| First Author | Rabani S | Year | 2024 |
| Journal | Cell Rep | Volume | 43 |
| Issue | 11 | Pages | 114920 |
| PubMed ID | 39466774 | Mgi Jnum | J:360637 |
| Mgi Id | MGI:7790362 | Doi | 10.1016/j.celrep.2024.114920 |
| Citation | Rabani S, et al. (2024) CD84 as a therapeutic target for breaking immune tolerance in triple-negative breast cancer. Cell Rep 43(11):114920 |
| abstractText | Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. The tumor microenvironment (TME) plays a major regulatory role in TNBC progression and is highly infiltrated by suppressive immune cells that reduce anti-tumor immune activity. Although regulatory B cells (Bregs) are a key TME component, knowledge of their function in TNBC is limited. CD84 is a homophilic adhesion molecule that promotes the survival of blood tumors. In the current study, we followed the role of CD84 in the regulation of the TME in TNBC. We demonstrate that CD84 induces a cascade in Bregs that involves the beta-catenin and Tcf4 pathway, which induces the transcription of interleukin-10 by binding to its promoter and the promoter of its regulator, AhR. This leads to the expansion of Bregs, which in turn control the activity of other immune cells and immune suppression. Accordingly, we suggest CD84 as a therapeutic target for breaking immune tolerance in TNBC. |
